AstraZeneca’s COVID-19 antibody cocktail only 33% effective

AstraZeneca Plc’s antibody cocktail was only 33% effective at preventing symptomatic COVID-19 in people who had been exposed to the virus, failing a study that was key to the drugmaker’s pandemic push.